CMA to consider undertakings offered
Theramex / European Rights to Viatris' Femoston and Duphaston Products
On 4 April 2024, the CMA decided, on the information currently available to it, that it is or may be the case that this Merger may be expected to result in a substantial lessening of competition within a market or markets in the United Kingdom.
On 11 April 2024, the Parties offered undertakings in lieu of a reference to the CMA, which involve the divestment of the UK rights to Femoston and Duphaston and provision of related assets. The CMA considers that there are reasonable grounds for believing that the undertakings offered by the Parties, or a modified version of them, might be accepted by the CMA to remedy the substantial lessening of competition identified by the CMA.
The CMA now has until 17 June 2024 to decide whether to accept the undertakings, with the possibility to extend this timeframe to 12 August 2024 if it considers there are special reasons for doing so.
The text of this decision will be placed on the Competition and Market Authority's web site at Theramex/European Rights to Viatris' Femoston and Duphaston products - GOV.UK (www.gov.uk) as soon as is reasonably practical.
In the event of media enquiries please email Press@cma.gov.uk
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
